HCV Treatment
IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
Experts Question Cochrane Review of Hepatitis C DAA Treatment
- Details
- Category: HCV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticized by doctors and advocates for its conclusion that there is no evidence that the expensive drugs prolong life or reduce liver-related disease in people who achieve a sustained virological response to treatment -- a cure, in current understanding.
IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection
- Details
- Category: HCV Treatment
- Published on Monday, 07 August 2017 00:00
- Written by Liz Highleyman
AbbVie's new 8-week pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C coinfection in the EXPEDITION-2 study, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
New Hepatitis C Drugs Reduce Mortality Risk in First 18 Months After Treatment
- Details
- Category: HCV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Michael Carter
For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality among people with hepatitis C virus (HCV) infection, according to a recent report in Clinical Infectious Diseases.
FDA Approves AbbVie's 8-Week Mavyret Combo Pill for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Monday, 07 August 2017 00:00
- Written by Liz Highleyman
On August 3 the U.S.Food and Drug Administration(FDA) approved AbbVie's new pangenotypic combination pill for people with hepatitis C virus (HCV) genotypes 1 through 6, to be marketed under the brand name Mavyret. Last week the European Commission gave similar approval for the European Union, where the coformulation will be sold as Maviret.
Web Design and Development by